Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Adas

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Rheumatology (Oxford, England)|June 30, 2025
The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors- a review of the literatureDeepak Nagra, Kaiyang Song, Joy Odia, et al.
Rheumatology (Oxford, England)|June 4, 2024
Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort studyDeepak Nagra, Katie Bechman, Mark D Russell, et al.
Rheumatology (Oxford, England)|November 1, 2024
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort studyMark D Russell, Zijing Yang, Niamh Dooley, et al.
The Lancet. Rheumatology|October 18, 2024
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort studyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
Annals of the Rheumatic Diseases|May 29, 2023
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indicationsMark D Russell, Christopher Stovin, Edward Alveyn, et al.
The Lancet. Rheumatology|November 30, 2022
Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELYMark D Russell, James B Galloway, Colm D Andrews, et al.
Rheumatology (Oxford, England)|June 5, 2025
Risk of infection in patients with early inflammatory arthritis: results from a large UK prospective observational cohort studyMaryam A Adas, Katie Bechman, Mark D Russell, et al.
The Lancet. Rheumatology|January 22, 2024
Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELYMark D Russell, Jon Massey, Edward Roddy, et al.
BMJ (Clinical Research Ed.)|January 21, 2026
Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELYMark D Russell, Andrea Schaffer, Katie Bechman, et al.
Rheumatology (Oxford, England)|November 6, 2023
Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flaresMark D Russell, Louise Ameyaw-Kyeremeh, Flora Dell'Accio, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Rheumatology (Oxford, England)|June 30, 2025
The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors- a review of the literatureDeepak Nagra, Kaiyang Song, Joy Odia, et al.
Rheumatology (Oxford, England)|June 4, 2024
Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort studyDeepak Nagra, Katie Bechman, Mark D Russell, et al.
Rheumatology (Oxford, England)|November 1, 2024
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort studyMark D Russell, Zijing Yang, Niamh Dooley, et al.
The Lancet. Rheumatology|October 18, 2024
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort studyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
Annals of the Rheumatic Diseases|May 29, 2023
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indicationsMark D Russell, Christopher Stovin, Edward Alveyn, et al.
The Lancet. Rheumatology|November 30, 2022
Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELYMark D Russell, James B Galloway, Colm D Andrews, et al.
Rheumatology (Oxford, England)|June 5, 2025
Risk of infection in patients with early inflammatory arthritis: results from a large UK prospective observational cohort studyMaryam A Adas, Katie Bechman, Mark D Russell, et al.
The Lancet. Rheumatology|January 22, 2024
Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELYMark D Russell, Jon Massey, Edward Roddy, et al.
BMJ (Clinical Research Ed.)|January 21, 2026
Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELYMark D Russell, Andrea Schaffer, Katie Bechman, et al.
Rheumatology (Oxford, England)|November 6, 2023
Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flaresMark D Russell, Louise Ameyaw-Kyeremeh, Flora Dell'Accio, et al.
Pageof 3